JBJ-09-063 (TFA)

JBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor with IC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 TFA effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 TFA is effective across EGFR tyrosine kinase inhibitor (TKI) -sensitive and resistant models. JBJ-09-063 TFA can be used for researching EGFR-mutant lung cancer[1].

C33H30F4N4O5S

670.67

O=C(NC1=NC=CS1)C(C2=CC(F)=CC=C2O)N(CC3=C4C=C(C5=CC=C(C6CCN(C)CC6)C=C5)C=C3)C4=O.O=C(O)C(F)(F)F

EGFR

EGFR/ErbB1/HER1

99.64

DMSO : ≥ 100 mg/mL

4°C (Powder, sealed storage, away from moisture)

Room Temperature